Author

W. Park

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer

Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define de...

M. Hilmi, J. Schoenfeld, Wilson H. McKerrow et al. · bioRxiv · 0 citations

Sep 2026

Abstract PR014: Integrated translational analyses of the first generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offers rational combination strategies in pancreatic cancer

KRAS G12D is a prevalent oncogenic driver in PDAC, which has a high unmet need due to few effective targeted therapies. Setidegrasib, a novel KRAS G12D-targeted protein degrader, eliminates the oncogenic driver to suppress downstream signaling and induce tumor cell death. Early clinical activity was reported in a...

W. Park, S. Kadam, A. Kasi et al. · Cancer Research · 0 citations